Patients with T3 and T4, lymph node metastasis, and Stage III and IV tumors had decreased DFS as compared to those without SALL3 methylation (P = 0.024, P = 0.029, and P = 0.008, respectively) (Fig. 3c, e, g). This evidence concerns the gene SALL3 and metastatic malignant neoplasm in the lymph nodes.